Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world effectiveness of l-glutamine in Texas Medicaid patients with sickle cell disease

Yahan Zhang, Hyeun Ah Kang, Kristin M. Richards et al. Nov 03, 2025 pp. 2665-2665 10.1182/blood-2025-2665

Abstract Introduction: Sickle cell disease (SCD) is a rare, inherited hemolytic anemia which is characterized by a range of acute and chroni...

Use of angiopoietin-2 as a biomarker in vascular anomalies beyond complex lymphatic anomalies

Svatava Merkle, Timothy LeCras, Kiersten Ricci et al. Nov 03, 2025 pp. 4877-4877 10.1182/blood-2025-4877

Abstract Introduction: The study of vascular anomalies (VA) is a rapidly evolving field with the recent discovery of som...

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Janine Joseph, Joseph Tario, Han Yu et al. Nov 03, 2025 pp. 1411-1411 10.1182/blood-2025-1411

Abstract Introduction Bone marrow biopsies (BMBx) are an integral part of the diagnosis and management of plasma cell disorders (PCD) becaus...

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Felicitas Schulz, Udo Holtick, Mareike Verbeek et al. Nov 03, 2025 pp. 5992-5992 10.1182/blood-2025-5992

Abstract Background: Sequential conditioning regimens are widely used to prepare patients with high-risk myeloid malignancies for allogeneic...

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis

Irenaeus Chan, Pu Zhang, Xiangyu Pan et al. Nov 03, 2025 pp. 4-4 10.1182/blood-2025-4

Abstract Therapy-related myeloid neoplasms (tMN) are a fatal consequence of exposure to oncologic therapy. Prior work has demonstrated that...

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Marco Ladetto, David Lavie, Tae Min Kim et al. Nov 03, 2025 pp. 5516-5516 10.1182/blood-2025-5516

Abstract Background: Despite progress made with combination therapies that include cyclophosphamide, doxorubicin and prednisone plus rituxim...

ASF1B promotes erythropoiesis by regulating the establishment and dynamics of H3.3 nucleosomes

Xiang Guo, Jinlei Liu, Xuemei Song et al. Nov 03, 2025 pp. 2884-2884 10.1182/blood-2025-2884

Abstract ASF1B, a histone chaperon, was synergistically expressed together with the H3f3a gene encoding the histone variant H3.3 during eryt...

The role of high-dose vitamin c in management of hematological malignancies: Asystematic review and meta-analysis

Zeeshan Sattar, Muhammad Kashif Amin, Hafiz Muhammad Hannan Javed et al. Nov 03, 2025 pp. 8116-8116 10.1182/blood-2025-8116

Abstract Introduction: Multiple studies have demonstrated the role of Vitamin C in normal hematopoiesis; however, its...

Characterization of participants with elevated bleeding rates responding to prophylactic marstacimab treatment in the phase 3 BASIS trial

Young-Shil Park, Fahri Sahin, Laurent Frenzel et al. Nov 03, 2025 pp. 4838-4838 10.1182/blood-2025-4838

Abstract Background Marstacimab, a monoclonal antibody targeting tissue factor pathway inhibitor to reduce inhibition of the extrinsic coagu...

Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms

Garima Pandey, Tegan Rowsell, Lucia Mazzacurati et al. Nov 03, 2025 pp. 5533-5533 10.1182/blood-2025-5533

Abstract The classical myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and primary myelofibrosis (MF) are...

Stability and evolution of individual-level biomarker patterns across repeated vaso-occlusive crises in sickle cell disease

Kim Summers, Orlando Agrippa, Alfonso Portabales et al. Nov 03, 2025 pp. 6222-6222 10.1182/blood-2025-6222

Abstract Background Vaso-occlusive crises (VOCs) in sickle cell disease (SCD) are recurrent, difficult-to-predict events that significantly...

Analysis of non-driver mutation characteristics in primary myelofibrosis

yueru luo, Yixuan Li, Xinhai Deng et al. Nov 03, 2025 pp. 7329-7329 10.1182/blood-2025-7329

Abstract Objective: This study aims to investigate the distribution characteristics, interrelationships, and impact on disease prognosis of...

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Clare Grieve, Esther Drill, Michelle Okwali et al. Nov 03, 2025 pp. 1008-1008 10.1182/blood-2025-1008

Abstract Background: Follicular lymphoma (FL), a largely incurable malignancy, has an indolent yet heterogenous course, with some patients (...

Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey.

Elisabetta Metafuni, Antonio De Vivo, Andrea Patriarca et al. Nov 03, 2025 pp. 4665-4665 10.1182/blood-2025-4665

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic disease characterized by complement-mediated intrav...

Analysis of cKIT mutations in Acute Myeloid Leukemia and systemic mastocytosis by multiplex SuperRCA® technology

Marina Lesnikova, Steven Kussick, Charles Ma et al. Nov 03, 2025 pp. 7020-7020 10.1182/blood-2025-7020

Abstract Introduction Alterations in cKIT residue D816 are the hallmark of systemic mastocytosis (SM) and are typically associated with poor...

Efficacy and safety of NTQ5082 monotherapy in complement-inhibitor-Naïve patients with paroxysmal nocturnal hemoglobinuria: A proof-of-concept, multicenter, randomized, open-label phase 2 study

Fengkui Zhang, Hongyan Tong, Linghui Xia et al. Nov 03, 2025 pp. 982-982 10.1182/blood-2025-982

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of hematopoietic stem cells characterized by...

Azole-adjusted venetoclax-based regimens in unfit AML patients: A real-world brazilian experience from a resource-limited setting

Pedro Perez, Renata Queiroz, André Américo et al. Nov 03, 2025 pp. 8187-8187 10.1182/blood-2025-8187

Abstract Background: Venetoclax-based regimens have become the standard of care for patients with newly diagnosed acute myeloid leukemia (AM...

Modeling disability reduction through low-dose prophylaxis versus on-demand therapy in hemophilia A: A meta-analysis and gbd-inspired yld framework for resource-limited settings

Muhammad Ahmed, Sweta Sahu, Salma Younas et al. Nov 03, 2025 pp. 3075-3075 10.1182/blood-2025-3075

Abstract Low-dose prophylaxis (LDP) is increasingly adopted in low- and middle-income countries (LMICs) as a cost-feasible approach to reduc...

Targeting pathogenic alloantibody generation using a chimeric HPA-1a-containing fc fusion protein: A novel treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT)

Huiying Zhi, Cathy Paddock, Guoping Fu et al. Nov 03, 2025 pp. 198-198 10.1182/blood-2025-198

Abstract Background: Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a rare, pregnancy-associated bleeding disorder caused by mate...

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia

Roberta S. Azevedo, Naval Daver, Omer Karrar et al. Nov 03, 2025 pp. 45-45 10.1182/blood-2025-45

Abstract Background: Patients (pts) with FLT3-mutated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, especially...

Spermine alleviates EV71-induced inflammation by inhibiting GBP5 and NLRP3 activation in macrophages

Zhihua Tian, Qingqing Yang, Xin Chen et al. Nov 03, 2025 pp. 4766-4766 10.1182/blood-2025-4766

Abstract Backgrounds Hand-foot-and-mouth disease (HFMD) is a common childhood infectious disease primarily caused by enteroviruses, with ent...

An investigation of somatic mutations in IDH genes in peripheral blood in the all of us research program

Huan Mo, Tracey Ferrara, Michelly Sampaio De Melo et al. Nov 03, 2025 pp. 6700-6700 10.1182/blood-2025-6700

Abstract Background: Somatic mutations in isocitrate dehydrogenase (IDH) genes are commonly seen in acute myeloid leukemia (AML) and other m...

AI-based, secure and privacy-preserving synthetic data generation platform in transfusion-dependent β-thalassemia applied to the Webthal® dataset

Mattia Delleani, Barbara Gianesin, Saverio D'Amico et al. Nov 03, 2025 pp. 4351-4351 10.1182/blood-2025-4351

Abstract Background While AI technologies for synthetic data (SD) generation are well-developed, their direct application in clinical settin...

Real-world efficacy and prognostic modeling of venetoclax-enhanced intensive chemotherapy in fit AML

Boyue Zheng, Jiyi Fu, Jiafei Wu et al. Nov 03, 2025 pp. 6985-6985 10.1182/blood-2025-6985

Abstract Objective: This study aimed to evaluate the efficacy and safety of Venetoclax combined with intensive chemotherapy in Fit AML patie...

Early versus late onset hematologic immune-related adverse events following immune checkpoint inhibition: Temporal patterns, clinical profiles, and risk stratification in faers reports (2014–2025)

Aftab Ahmed, Manzer Ali, Rajesh Thirumaran et al. Nov 03, 2025 pp. 7659-7659 10.1182/blood-2025-7659

Abstract Background: Hematologic immune-related adverse events (hem-irAEs) are rare but severe complications of immune c...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page